Source: BioSpace, by Michael Gibney (September 16, 2026). AI-generated summary by biochip.com, published . Not independently reviewed.
Key takeaways
- FDA cleared Aptitude’s next-generation Metrix COVID Test through 510(k), the company’s first clearance under that pathway.
- Aptitude says the cleared Metrix COVID Test has approximately threefold greater analytical sensitivity and delivers results 30% faster.
- Metrix COVID/Flu remains under FDA review, while COVID medical-device EUA declarations are scheduled to end December 26, 2026.
Aptitude Medical Systems has received U.S. Food and Drug Administration 510(k) clearance for its next-generation Metrix COVID Test, moving the company’s compact molecular testing system beyond its earlier emergency authorization. The clearance is Aptitude’s first 510(k) clearance and applies to a test intended for both over-the-counter use and professional use in Clinical Laboratory Improvement Amendments (CLIA)-waived settings. Metrix is a handheld molecular diagnostics platform, meaning it detects genetic material associated with an infectious agent rather than relying on simpler signal-detection formats. Aptitude says the updated COVID test delivers about three times greater analytical sensitivity than the original emergency use authorized version. It also reports results 30% faster. The Biomedical Advanced Research and Development Authority, a U.S. government organization that supports preparedness technologies, supported development of the test. The regulatory decision arrives as Aptitude works to shift its broader respiratory testing portfolio from emergency authorization into traditional FDA clearance pathways. The company is also positioning Metrix for decentralized settings, particularly urgent care clinics that may have lacked the space, budget, or operational capacity for conventional molecular systems.
What FDA 510(k) Clearance Means
A 510(k) clearance is an FDA marketing pathway for medical devices that are shown to be substantially equivalent to a legally marketed predicate device. It differs from the emergency use authorization, or EUA, mechanism that helped make certain diagnostic products available during the COVID-19 public health emergency.
For Aptitude, the decision marks a regulatory milestone because it is the company’s first 510(k) clearance. The next-generation Metrix COVID Test replaces neither every earlier product nor every regulatory step facing the company, but it establishes a cleared respiratory test within the Metrix platform.
A More Sensitive, Faster COVID Test
Aptitude says the new test offers approximately threefold greater analytical sensitivity than the original EUA-authorized Metrix COVID product. Analytical sensitivity describes how well a test can detect small amounts of a target, much like a microphone that can pick up a quieter sound.
In this case, the target is genetic material from the virus that causes COVID-19. Aptitude also says the updated assay produces results 30% faster, combining the improved detection claim with a shorter testing time.
A Handheld Platform for Decentralized Care
Metrix was designed as a small molecular testing system that can fit in a hand. Aptitude frames its goal as bringing high-performance molecular diagnostics to locations outside centralized laboratories, including urgent care sites and other decentralized health care settings.
That matters because molecular testing systems have often come with practical constraints: large instruments, fixed testing capacity, complicated workflows, upfront equipment costs, and purchasing commitments. A compact platform is meant to work more like a countertop appliance than a full commercial kitchen, allowing a clinic to run molecular tests without building a traditional laboratory workflow around a large instrument.
Use in Homes and CLIA-Waived Sites
The cleared Metrix COVID Test is intended for over-the-counter use as well as professional use in CLIA-waived settings. CLIA waivers apply to certain tests that meet federal criteria for simplicity and low risk of incorrect results, enabling them to be used in places that do not operate as high-complexity clinical laboratories.
Aptitude’s stated focus is on making molecular testing more practical in these locations. The company reports that hundreds of clinics adopted the Metrix platform over the past year, with urgent care representing a particular area of commercial adoption.
COVID and Flu Test Remains Under Review
Aptitude’s next-generation Metrix COVID/Flu Test is still under FDA review for 510(k) clearance. The company is pursuing that clearance as part of a wider transition of its respiratory testing products away from emergency authorization and toward traditional FDA authorization.
The timing is tied to the scheduled termination of COVID-19 EUA declarations for medical devices on December 26, 2026, following an announcement by the U.S. Department of Health and Human Services. Aptitude says it does not expect disruption to Metrix product availability during the upcoming respiratory season.
What Happens to Earlier EUA Products
Customers can continue purchasing Metrix products while the regulatory transition proceeds, Aptitude said. The company also states that previously distributed Metrix products authorized under an EUA may continue to be used through the expiration dates printed on their labels, consistent with FDA transition policies.
Metrix is available through major distributors in collaboration with Aptitude’s commercial partner, Sekisui Diagnostics. That distribution arrangement is part of the company’s effort to broaden access as it updates its respiratory test menu and regulatory status.
A Broader Menu Is in Development
Aptitude is developing additional tests for respiratory syncytial virus, commonly called RSV, strep throat, and sexually transmitted infections. The company says these products are in late-stage development or under FDA review, although it did not provide clearance dates or performance data for those tests.
The strategy is to use the same Metrix platform for multiple conditions rather than treating the COVID test as a standalone product. A broader test menu can make a diagnostic instrument more useful to a clinic because the same basic system can support decisions across several common infectious-disease needs.
Why This Matters
The clearance illustrates the next phase of the COVID diagnostics market: products initially deployed under emergency rules are moving through conventional regulatory review. For a platform like Metrix, the important point is not only that one COVID assay has been cleared, but that the system is being built for molecular testing in settings where larger laboratory instruments have been difficult to deploy.
Aptitude’s claims of greater analytical sensitivity and faster results suggest a technical upgrade over its original Metrix COVID test, while the 510(k) decision gives the company a more durable regulatory foundation as EUA policies wind down. The practical test will be whether the platform’s compact format, workflow, and expanding assay menu can sustain use across urgent care and other decentralized care locations in the years ahead.